Serum type III procollagen peptide concentrations in systemic sclerosis and raynaud's phenomenon: Relationship to disease activity and duration

Rheumatology

Volumn 28, Issue 2, 1989, Pages 98-103

  Black, Carol M ^a   Mcwhirter, A ^a   Harrison, N K ^b   Kirk, J M E ^b   Laurent, G J ^b  

^a WEST MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Disease activity; Raynaud's; Systemic sclerosis; Type III procollagen peptide

Indexed keywords

COLLAGEN TYPE 3;

ADULT; AGED; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SERODIAGNOSIS;

ADULT; AGED; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGE; OSMOLAR CONCENTRATION; PEPTIDE FRAGMENTS; PROCOLLAGEN; RAYNAUD'S DISEASE; SCLERODERMA, SYSTEMIC; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0024590005     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/28.2.98     Document Type: Article

References (24)

1. Rodnan GP. Progressive systemic sclerosis (scleroderma). In: McCarty DJ, ed. Arthritis and allied conditions. 9th ed. Philadelphia: Lea and Febiger, 1979: 762–809.
2. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975;4:351–68.
3. Timpl R, Glanville RW. The aminopropeptide of collagen. Clin Orthopaed 1981; 158: 224–42.
4. Fessler JH, Fessler LI. Biosynthesis of procollagens. Annu Rev Biochem 1978;47:129–62.
5. Rohde H, Vargas L, Hahn E, Kalbfleisch H, Bruguera M, Timpl R. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 1979;9:451–9.
6. Niemala O, Risteli L, Sotaniemi EA, Risteli J. Aminoterminal propeptide of type III procollagen in serum in alcoholic liver disease. Gastroenterology 1983;85:254–9.
7. Morelli A, Vedovelli A, Fiorucci S, et al. Type III procollagen peptide and PZ-peptidase serum levels in pre-sclerotic liver diseases. Clin Chim Acta 1985;148:87–95.
8. Hahn EG. Blood analysis for liver fibrosis. J Hepatol 1984;1:67–73.
9. Kirk JME, Bateman ED, Haslam PL, Laurent GJ, Turner-Warwick M. Serum type III procollagen peptide concentration in cryptogenic fibrosing alveolitis and clinical relevance. Thorax 1984;39:726–32.
10. Horslev-Petersen K, Bentsen KD, Junker P, Lorenzen I. Serum amino-terminal type III procollagen peptide in rheumatoid arthritis. Arthritis Rheum 1986;29:592–9.
11. McWhirter A, Kirk J ME, Black CM, Laurent GJ. Serum Type-III procollagen peptide concentration in systemic sclerosis and Raynaud’s phenomenon (meeting abstract). Clin Sci 1987;72(S16):69.
12. Krieg T, Langer I, Gerstmeier H. Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol 1986; 87:788–91.
13. Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–90.
14. Medsger T. Classification of scleroderma. In: Black CM, Jayson MIV, eds. Systemic sclerosis: scleroderma. London: John Wiley, 1988: 1–6.
15. Hughes P, Holt S, Rowell NR, Dodd JK. Thymus dependent (T) lymphocyte deficiency in progressive systemic sclerosis. Br J Dermatol 1976;95:469–73.
16. Instruction booklet for RIA-gnost® Prokollagen-III-Peptid Kit (Behringswerke AG, Marburg, Germany).
17. Rohde H, Langer I, Krieg T, Timpl R. Serum and urine analysis of the aminoterminal procollagen peptide type III by radioimmunoassay with antibody Fab fragments. Collagen Rel Res 1983;3:371–9.
18. Waterlow JC, Garlich PJ, Millward DJ. Protein turnover in mammalian tissues and in the whole body. Amsterdam, New York, Oxford: North Holland Publishing Company, 1978.
19. Veis A, Anesey J, Yuan L, Levy SJ. Evidence for an amino-terminal extension in high-molecular-weight collagens from mature bovine skin. Proc Natl Acad Sci USA 1973;70:1464–7.
20. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974;54:880–9.
21. Krieg T, Luderschmidt C, Weber L, Muller PK, Braun-Falco O. Scleroderma fibroblasts: some aspects of in vitro assessment of collagen synthesis. Arch Dermatol Res 1981;270:263–72.
22. Peltonen L, Palotie A, Myllylä R, Kreig T, Oikarinea A. Collagen biosynthesis in systemic scleroderma: regulation of post-translational modifications and synthesis of procollagen in cultured fibroblasts. J Invest Dermatol 1985;84:14–18.
23. Uitto J, Bauer EA, Eisen AZ. Scleroderma: increased biosynthesis of triple-helical type I and type III procollagen associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest 1979;64:921–30.
24. Vuorio TK, Kahari VM, Lehtonen A, Vuorio E. Fibroblast activation in scleroderma. Scand J Rheumatol 1984;13:229–37.